Skip to menu Skip to content Skip to footer
Professor Victoria Atkinson
Professor

Victoria Atkinson

Email: 

Overview

Background

Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.

Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.

In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.

She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.

Availability

Professor Victoria Atkinson is:
Available for supervision

Research interests

  • Oncology

  • Melanoma

  • Gastro-intestinal oncology

  • Patient outcomes

Works

Search Professor Victoria Atkinson’s works on UQ eSpace

113 works between 2011 and 2024

41 - 60 of 113 works

2020

Journal Article

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Ascierto, Paolo A., Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Maio, Michele, Middleton, Mark R., de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Lobo, Maurice, de Pril, Veerle, Loffredo, John, Larkin, James and Weber, Jeffrey (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 21 (11), 1465-1477. doi: 10.1016/S1470-2045(20)30494-0

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Featured

2020

Journal Article

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

Aoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

2020

Journal Article

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

Dummer, Reinhard, Lebbé, Celeste, Atkinson, Victoria, Mandalà, Mario, Nathan, Paul D., Arance, Ana, Richtig, Erika, Yamazaki, Naoya, Robert, Caroline, Schadendorf, Dirk, Tawbi, Hussein A., Ascierto, Paolo A., Ribas, Antoni, Flaherty, Keith T., Pakhle, Neha, Campbell, Catarina D., Gusenleitner, Daniel, Masood, Aisha, Brase, Jan C., Gasal, Eduard and Long, Georgina V. (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 26 (10), 1557-1563. doi: 10.1038/s41591-020-1082-2

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

2020

Journal Article

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions

Gebhardt, Christoffer, Ascierto, Paolo, Atkinson, Victoria, Corrie, Pippa, Dummer, Reinhard and Schadendorf, Dirk (2020). The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. European Journal of Cancer, 138, 68-76. doi: 10.1016/j.ejca.2020.07.016

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions

2020

Journal Article

Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Carlino, Matteo S., Menzies, Alexander M., Atkinson, Victoria, Cebon, Jonathan S., Jameson, Michael B., Fitzharris, Bernard M., McNeil, Catriona M., Hill, Andrew G., Ribas, Antoni, Atkins, Michael B., Thompson, John A., Hwu, Wen-Jen, Hodi, F. Stephen, Guminski, Alexander D., Kefford, Richard, Wu, Haiyan, Ibrahim, Nageatte, Moreno, Blanca Homet and Long, Georgina V. (2020). Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research, 26 (19), 5086-5091. doi: 10.1158/1078-0432.CCR-20-0177

Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

2020

Journal Article

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Dummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M., Chiarion Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V. and Schadendorf, Dirk (2020). Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. The New England Journal of Medicine, 383 (12), 1139-1148. doi: 10.1056/NEJMoa2005493

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

2020

Journal Article

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

Hultin, Sebastian, Nahar, Kazi, Menzies, Alexander M., Long, Georgina V., Fernando, Suran L., Atkinson, Victoria, Cebon, Jonathan and Wong, Muh Geot (2020). Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrology, 21 (1) 391, 1-9. doi: 10.1186/s12882-020-02044-9

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

2020

Journal Article

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

Dummer, Reinhard, Brase, Jan C., Garrett, James, Campbell, Catarina D., Gasal, Eduard, Squires, Matthew, Gusenleitner, Daniel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Flaherty, Keith, Larkin, James, Robert, Caroline, Kefford, Richard, Kirkwood, John M., Hauschild, Axel, Schadendorf, Dirk and Long, Georgina V. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The Lancet Oncology, 21 (3), 358-372. doi: 10.1016/S1470-2045(20)30062-0

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

2020

Journal Article

Intratumoural immunotherapies in oncology

Xu, Wen, Atkinson, Victoria G. and Menzies, Alexander M. (2020). Intratumoural immunotherapies in oncology. European Journal of Cancer, 127, 1-11. doi: 10.1016/j.ejca.2019.12.007

Intratumoural immunotherapies in oncology

2020

Journal Article

Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma

Mason, Robert, Dearden, Helen C., Nguyen, Bella, Oon, Jennifer S., Smith, Jessica Louise, Randhawa, Manreet, Mant, Andrew, Warburton, Lydai, Lo, Serigne, Meniawy, Tarek, Guminski, Alexander, Parente, Phillip, Ali, Sayed, Haydon, Andrew, Long, Georgina V., Carlino, Matteo S., Millward, Michael, Atkinson, Victoria G. and Menzies, Alexander M. (2020). Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell and Melanoma Research, 33 (2) pcmr.12831, 358-365. doi: 10.1111/pcmr.12831

Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma

2020

Journal Article

Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial

Eggermont, Alexander M. M., Kicinski, Michal, Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, Van Den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C., Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Van Akkooi, Alexander, Robert, Caroline and Suciu, Stefan (2020). Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncology, 6 (4), 519-527. doi: 10.1001/jamaoncol.2019.5570

Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial

2020

Journal Article

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M. A., Millward, M., Patel, S. P., Haydon, A., Johnson, D. B., Lo, S., Blank, C. U., Sandhu, S., Carlino, M. S., Larkin, J. M.G., Menzies, A. M. and Long, G. V. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Annals of Oncology, 31 (8), 1075-1082. doi: 10.1016/j.annonc.2020.04.471

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

2020

Journal Article

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

Bhave, Prachi, Pallan, Lalit, Long, Georgina V., Menzies, Alexander M., Atkinson, Victoria, Cohen, Justine V., Sullivan, Ryan J., Chiarion-Sileni, Vanna, Nyakas, Marta, Kahler, Katharina, Hauschild, Axel, Plummer, Ruth, Trojaniello, Claudia, Ascierto, Paolo A., Zimmer, Lisa, Schadendorf, Dirk, Allayous, Clara, Lebbe, Celeste, Maurichi, Andrea, Santinami, Mario, Roy, Severine, Robert, Caroline, Lesimple, Thierry, Patel, Sapna, Versluis, Judith M., Blank, Christian U., Khattak, Adnan, Van der Westhuizen, Andre, Carlino, Matteo S. ... Haydon, Andrew (2020). Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer, 124 (3), 574-580. doi: 10.1038/s41416-020-01121-y

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

2020

Journal Article

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

Atkinson, Victoria, Sandhu, Shahneen, Hospers, Geke, Long, Georgina V., Aglietta, Massimo, Ferrucci, Pier F., Tulyte, Skaiste, Cappellini, Gian Carlo Antonini, Soriano, Virtudes, Ali, Sayed, Poprach, Alexandr, Cesas, Alvydas, Rodriguez-Abreu, Delvys, Lau, Mike, De Jong, Egbert, Legenne, Philippe, Stein, Dara, King, Brianna and Van Thienen, Johannes V. (2020). Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 30 (3), 261-267. doi: 10.1097/CMR.0000000000000654

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

2019

Journal Article

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador, Hinshelwood, Rebecca, Mesnage, Soizick, Cebon, Jonathan, Ferrucci, Pier Francesco, Aglietta, Massimo, Neyns, Bart, Chiarion-Sileni, Vanna, Lindsay, Colin R., Del Vecchio, Michele, Linardou, Helen, Merelli, Barbara, Tonini, Giuseppe, Atkinson, Victoria, Freivogel, Klaus, Stein, Dara, Dalland, Lindi, Lau, Mike, Legenne, Philippe, Queirolo, Paola and Millward, Michael (2019). Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 29 (5), 527-532. doi: 10.1097/CMR.0000000000000608

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

2019

Journal Article

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies

Pires da Silva, Ines, Glitza, Isabella C., Haydu, Lauren E., Johnpulle, Romany, Banks, Patricia D., Grass, George D., Goldinger, Simone M. A., Smith, Jessica L., Everett, Ashlyn S., Koelblinger, Peter, Roberts-Thomson, Rachel, Millward, Michael, Atkinson, Victoria G., Guminski, Alexander, Kapoor, Rony, Conry, Robert M., Carlino, Matteo S., Wang, Wei, Shackleton, Mark J., Eroglu, Zeynep, Lo, Serigne, Hong, Angela M., Long, Georgina V., Johnson, Douglas B. and Menzies, Alexander M. (2019). Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 32 (4), 553-563. doi: 10.1111/pcmr.12775

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies

2019

Journal Article

Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature

Xu, Wen, Moor, Rebecca J., Walpole, Euan T. and Atkinson, Victoria G. (2019). Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Research, 29 (3), 333-337. doi: 10.1097/CMR.0000000000000586

Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature

2019

Journal Article

Reply to E. Hindié and K.R. Hess

Long, Georgina V., Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M. and Hauschild, Axel (2019). Reply to E. Hindié and K.R. Hess. Journal of Clinical Oncology, 37 (15), 1356-1358. doi: 10.1200/JCO.19.00004

Reply to E. Hindié and K.R. Hess

2019

Journal Article

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

Schadendorf, Dirk, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Lesimple, Thierry, Plummer, Ruth, Schachter, Jacob, Dasgupta, Kohinoor, Manson, Stephanie, Koruth, Roy, Mookerjee, Bijoyesh, Kefford, Richard, Dummer, Reinhard, Kirkwood, John M. and Long, Georgina V. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 20 (5), 701-710. doi: 10.1016/S1470-2045(18)30940-9

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

2019

Conference Publication

Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibition

Agarwala, Sanjiv S., Ross, Merrick I., Zager, Jonathan, Shirai, Keisuki, Essner, Richard, Smithers, Bernard M., Atkinson, Victoria, Sarson, David and Wachter, Eric A. (2019). Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibition. LONDON: BMC.

Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibition

Funding

Current funding

  • 2023 - 2026
    Assessment of tumour phenotype for precision medicine in oesophageal cancer via deep learning analysis of medical images
    CCQ Accelerating Collaborative Cancer Research
    Open grant
  • 2021 - 2025
    Novel predictive disease modelling using liquid biopsies to improve outcomes in melanoma (MRFF Genomics Health Futures Mission grant led by the University of Melbourne)
    University of Melbourne
    Open grant
  • 2020 - 2025
    Circulating tumour DNA guidEd Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION) (MRFF ICTC led by University of Melbourne)
    University of Melbourne
    Open grant
  • 2018 - 2025
    A Randomised Phase III Study of the duration of the Anti-PD1 - therapy in metastatic melanoma (STOP-GAP)
    NHMRC Project Grant
    Open grant

Past funding

  • 2020 - 2021
    Cancer Evolution Biobank
    PA Research Foundation
    Open grant

Supervision

Availability

Professor Victoria Atkinson is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Professor Victoria Atkinson's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au